Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): An open-label, non-inferiority, randomised controlled trial
Kathy Pritchard-Jones, Christophe Bergeron, Beatriz De Camargo, Marry M. Van Den Heuvel-Eibrink, Tomas Acha, Jan Godzinski, Foppe Oldenburger, Liliane Boccon-Gibod, Ivo Leuschner, Gordan Vujanic, Bengt Sandstedt, Jan De Kraker, Harm Van Tinteren, Norbert Graf
Research output: Contribution to journal › Article › peer-review
164Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): An open-label, non-inferiority, randomised controlled trial'. Together they form a unique fingerprint.